Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) EBITDA: 2020-2021

Historic EBITDA for Cardiol Therapeutics (CRDL) over the last 2 years, with Dec 2021 value amounting to -$25.2 million.

  • Cardiol Therapeutics' EBITDA rose 22.36% to -$6.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$7.2 million, marking a year-over-year change of. This contributed to the annual value of -$25.2 million for FY2021, which is 63.85% down from last year.
  • Latest data reveals that Cardiol Therapeutics reported EBITDA of -$25.2 million as of FY2021, which was down 63.85% from -$15.4 million recorded in FY2020.
  • Over the past 5 years, Cardiol Therapeutics' EBITDA peaked at -$15.4 million during FY2020, and registered a low of -$25.2 million during FY2021.
  • For the 2-year period, Cardiol Therapeutics' EBITDA averaged around -$20.3 million, with its median value being -$20.3 million (2020).
  • Data for Cardiol Therapeutics' EBITDA shows a maximum YoY plummeted of 63.85% (in 2021) over the last 5 years.
  • Over the past 2 years, Cardiol Therapeutics' EBITDA (Yearly) stood at -$15.4 million in 2020, then slumped by 63.85% to -$25.2 million in 2021.